Genfit S.A. (NASDAQ:GNFT – Free Report) – Analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for shares of Genfit in a report released on Thursday, September 19th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn $0.65 per share for the year, up from their previous estimate of $0.52. The consensus estimate for Genfit’s current full-year earnings is $0.56 per share.
Separately, HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Genfit in a research report on Friday.
Genfit Stock Performance
Genfit stock opened at $4.99 on Monday. The company has a quick ratio of 2.94, a current ratio of 2.94 and a debt-to-equity ratio of 0.92. Genfit has a 12 month low of $2.89 and a 12 month high of $6.05. The company has a fifty day moving average price of $4.24 and a two-hundred day moving average price of $4.07.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Genfit stock. Optiver Holding B.V. raised its stake in Genfit S.A. (NASDAQ:GNFT – Free Report) by 2,229.2% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 82,359 shares of the company’s stock after buying an additional 78,823 shares during the quarter. Optiver Holding B.V. owned approximately 0.17% of Genfit worth $315,000 as of its most recent SEC filing. 2.24% of the stock is owned by hedge funds and other institutional investors.
About Genfit
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Further Reading
- Five stocks we like better than Genfit
- How Investors Can Find the Best Cheap Dividend Stocks
- The Average 401k Balance by Age Explained
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Compound Interest and Why It Matters When Investing
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.